# EDGAR Filing Document

**Accession Number:** 0001690585
**File Stem:** 0001690585-26-000021
**Filing Date:** 2026-5
**Character Count:** 26223
**Document Hash:** 01f066b0da1921e013a2c6e87b33c3e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001690585-26-000021.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001690585-26-000021

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260505

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dianthus Therapeutics, Inc. /DE/
- **CENTRAL INDEX KEY:** 0001690585
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38541
- **FILM NUMBER:** 26942890

**BUSINESS ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 929-999-4055

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Magenta Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20161121

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** May 5, 2026<br>

------

DIANTHUS THERAPEUTICS, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-38541 | 81-0724163 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 7 Times Square<br>43rd Floor |  |  |
| New York**,** New York |  | 10036 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 929 999-4055<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 Par Value | DNTH | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 2.02 Results of Operations and Financial Condition.
On May 5, 2026, Dianthus Therapeutics, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [<u>Press release, dated May 5, 2026</u>](dnth-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **DIANTHUS THERAPEUTICS, INC.** |
| Date: | May 5, 2026 | By:  | /s/ Adam M. Veness, Esq. |
|  |  |  | Adam M. Veness, Esq.<br>SVP, General Counsel and Secretary |

---

------

## Exhibit 99.1

# Exhibit 99.1

# ![img85518887_0.gif](img85518887_0.gif)

# DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS

# AND REPORTS Q1 2026 FINANCIAL RESULTS
*Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A* 

*Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis*

*Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) on track to initiate in mid-2026; top-line results anticipated in 2H'28*

*Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for Q4'26*

*Phase 1 healthy volunteer data for DNTH212 anticipated in 2H'26*

*Building a rheumatology franchise around DNTH212 with first three priority indications of Sjögren's Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM)* 

*Further strengthened the balance sheet with approximately $719 million in gross proceeds from an underwritten public offering of common stock and pre-funded warrants* 

*Approximately $1.2 billion of cash as of March 31, 2026 provides expected runway into 2030*

**New York City and Waltham, Mass., May 5, 2026** – Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the first quarter ending March 31, 2026, and provided an update on other recent business achievements.

"Q1 of this year was a pivotal period for Dianthus as we were able to make an early GO decision in PART A of the claseprubart CIDP CAPTIVATE study. In CAPTIVATE, we targeted 40 patients completing Part A and a response rate of approximately 50% based on precedent set with aC1s inhibition. We were able to make an early GO decision after 20 confirmed responders were identified with less than the 40 planned participants completing Part A. Claseprubart potency and early efficacy and safety results in CAPTIVATE Part A further build our confidence in claseprubart as a potentially best-in-disease therapy for neuromuscular diseases," said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. "We are also excited to announce the first three priority indications selected for DNTH212, our first-in-class bifunctional fusion protein and next potential best-in-disease pipeline therapeutic: Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis. These are areas of high unmet need, where compelling biological rationale and clinical data support the complementary potential of targeting both BDCA2 and BAFF/APRIL to drive differentiated efficacy compared to single-mechanism approaches. Together, these indications represent a strong foundation for establishing a synergistic

www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036

------

rheumatology franchise around DNTH212, alongside the synergistic neuromuscular franchise we are building with claseprubart in gMG, CIDP and MMN."

**<u>Claseprubart (DNTH103) Clinical Development</u>**

Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks. Claseprubart has the potential to be a best-in-disease pipeline-in-a-product across a range of autoimmune disorders with high unmet need.

**Generalized Myasthenia Gravis (gMG)**

• **Phase 3 EMERGE trial on track to initiate in mid-2026, with top-line results expected in 2H'28:** Following the successful completion of our end-of-Phase 2 meeting with the FDA in the first quarter of 2026, a Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W S.C. and 300mg/2mL Q4W S.C. in gMG patients is on track to initiate in mid-2026, with top-line results expected in 2H'28.

• **Orphan Drug Designation granted:** Claseprubart was granted Orphan Drug Designation by the FDA for the treatment of Myasthenia Gravis. The FDA's Office of Orphan Products Development grants orphan designation to drugs and biologics intended to treat rare diseases affecting fewer than 200,000 people in the United States. Orphan Drug Designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval.

• **Claseprubart data presented at the 2026 American Academy of Neurology (AAN) Annual Meeting:** Two presentations describing results from the Phase 2 MaGic trial of claseprubart in gMG and *in vitro* data supporting the potential mechanistic advantages of aC1s inhibition are available on the Investors section of the Dianthus website under **<u>Scientific Publications</u>**.

**Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)**

• **Early GO decision announced in Phase 3 <u>CAPTIVATE trial</u>** in March 2026**:** The target for the Part A interim responder analysis was a response rate of 50% or greater (i.e., ≥20 confirmed responders out of first 40 participants to complete Part A) based on precedent set with aC1s inhibition. This GO decision was reached early, after 20 confirmed responders were achieved with less than 40 planned participants completing open-label Part A of the trial. Dianthus expects to provide CAPTIVATE Part B top-line guidance by YE'26.

**Multifocal Motor Neuropathy (MMN)**

• **Phase 2 <u>MoMeNtum trial</u> on track for top-line results in Q4'26:** The MoMeNtum trial is an ongoing global, randomized, double-blind, placebo-controlled Phase 2 trial in patients with MMN, with top-line results on track for Q4'26.

**All Programs**

In March 2026, the Company filed an **<u>8K</u>** indicating receipt of written feedback from FDA agreeing to three proposals for all ongoing and planned future claseprubart trials:

• Removal of anti-nuclear antibodies ("ANAs") as a screening criteria, a common reason for screen failure across all three claseprubart programs;

• Removal of routine ANA testing during claseprubart clinical trials; and

• Reclassification of the hypothetical risk of SLE to drug-induced lupus (DIL), a side effect in several classes of widely used medications characterized by the reversal of symptoms upon discontinuation of the precipitating medication.

www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036

------

Of note, there have been no cases of either SLE or DIL to date in any claseprubart program.

**<u>DNTH212 Clinical Development</u>**

DNTH212 is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes.

• **Initial indications selected for DNTH212 clinical development:** SjD, SLE, and DM have been selected as the first three priority indications for DNTH212 clinical development and will serve as the foundation of a synergistic rheumatology franchise for DNTH212.

• **Phase 1 data anticipated in 2H'26:** A **<u>two-part Phase 1 study</u>** in China in healthy volunteers (Part A) and patients with systemic lupus erythematosus (Part B) was initiated in December 2025, with top-line results in healthy volunteers expected in 2H'26. Upon completion of the Phase 1 study, Dianthus plans to provide an update on next steps for advancing its priority indications in clinical development.

**<u>Corporate Updates:</u>**

On March 12, Dianthus announced the **<u>closing of an upsized underwritten public offering</u>** of common stock and pre-funded warrants, with aggregate gross proceeds of approximately $719 million.

**<u>First-Quarter 2026 Financial Results</u>**

• **Cash Position** – Approximately $1.2 billion of cash, cash equivalents and investments as of March 31, 2026 is projected to provide runway into 2030.

• **R&D Expenses** – Research and development (R&D) expenses for the quarter ended March 31, 2026 were $34.5 million, inclusive of $4.8 million of stock-based compensation, compared to $27.0 million for the quarter ended March 31, 2025, which included $2.5 million of stock-based compensation. This increase in R&D expenses was primarily driven by higher clinical costs and increased headcount to support claseprubart Phase 2 and Phase 3 development.

• **G&A Expenses** – General and administrative (G&A) expenses for the quarter ended March 31, 2026 totaled $12.5 million, inclusive of stock-based compensation of $5.8 million, compared to $7.3 million for the quarter ended March 31, 2025, which included $2.8 million of stock-based compensation. This increase in G&A expenses was primarily due to increased headcount.

• **Net Loss** – Net loss for the quarter ended March 31, 2026 was $40.8 million or $0.85 per share (basic and diluted) compared to $29.5 million or $0.82 per share (basic and diluted) for the quarter ended March 31, 2025.

• **Additional Information** – For additional information on the Company's financial results for the quarter ended March 31, 2026, please refer to the Form 10-Q filed with the SEC.

www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036

------

**About Claseprubart (DNTH103)**<br>Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. As the classical pathway plays a significant role in disease pathology, claseprubart has the potential to be a best-in-disease pipeline-in-a-product across a range of autoimmune disorders with high unmet need. Dianthus is building a neuromuscular franchise with claseprubart and expects to initiate a Phase 3 trial in generalized Myasthenia Gravis in mid-2026, with top-line results expected in 2H'28, report top-line data from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in Q4'26, and provide an update on timing of top-line data from Part B of the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy by YE'26.

Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.

**About DNTH212**<br>DNTH212 is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes. Dianthus is building a rheumatology franchise with DNTH212 and has selected Sjögren's Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM) as the first three prioritized indications for clinical development. A two-part Phase 1 study in China in healthy volunteers (Part A) and patients with systemic lupus erythematosus (Part B) is ongoing, with top-line results in healthy volunteers expected in 2H'26.

DNTH212 is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.

**About Dianthus Therapeutics**

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit <u>www.dianthustx.com</u> and follow us on <u>LinkedIn</u>.

**Cautionary Statement Regarding Forward-Looking Statements** 

Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding future plans and prospects, including statements regarding the expectations or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to claseprubart and DNTH212, and any developments or results in connection therewith, including the target product profile and administration of claseprubart and DNTH212; the anticipated timing of the initiation and results from those studies and trials; expectations regarding the clinical trial designs or indications; expectations

www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036

------

regarding the time period over which the Company's capital resources are expected to be sufficient to fund its anticipated operations; and expectations regarding market size, patient population size, and potential opportunities for complement therapies, in particular with respect to claseprubart and DNTH212. Claseprubart and DNTH212 are investigational agents that are not approved as therapies in any indication in any jurisdiction worldwide. The words "opportunity," "potential," "milestones," "runway," "will," "anticipate," "achieve," "near-term," "catalysts," "pursue," "pipeline," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "predict," "project," "should," "strive," "would," "aim," "target," "commit," and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and DNTH212 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the preliminary interim analysis based on a limited number of patients from the Part A open label portion of the claseprubart CAPTIVATE study in patients with CIDP may not be predictive of the results or success of the remaining patients treated in Part A or patients treated in Part B of the CAPTIVATE study, that the development of claseprubart or DNTH212 may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company's compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company's compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" included in the Company's Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

**Contact** 

Jennifer Davis Ruff

Dianthus Therapeutics

<u>jdavisruff@dianthustx.com</u>

www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036

------

**DIANTHUS THERAPEUTICS, INC.** 

**Consolidated Balance Sheets** 

**(unaudited, in thousands)** 

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $627667 | $51087 |
| &nbsp;&nbsp;&nbsp;Short-term investments | 483592 | 353208 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 1230 | 52 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 7422 | 5091 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1119911 | 409438 |
| Long-term investments | 113868 | 110135 |
| Property and equipment, net | 274 | 296 |
| Right-of-use operating lease assets | 1293 | 1337 |
| Other assets and restricted cash | 11538 | 9716 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1246884 | $530922 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $5274 | $9725 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 31125 | 19452 |
| &nbsp;&nbsp;&nbsp;Current portion of deferred revenue | 1485 | 1188 |
| &nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | 399 | 367 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 38283 | 30732 |
| Deferred revenue | 6322 | 5770 |
| Long-term operating lease liabilities | 965 | 1019 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 45570 | 37521 |
| Commitments and contingencies |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock  |  |  |
| &nbsp;&nbsp;&nbsp;Common stock | 54 | 43 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 1579398 | 829598 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (377563) | (336729) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive (loss)/income | (575) | 489 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 1201314 | 493401 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $1246884 | $530922 |

---

www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036

------

**DIANTHUS THERAPEUTICS, INC.** 

**Condensed Consolidated Statements of Operations and Comprehensive Loss** 

**(in thousands, except share and per share data)** 

**(unaudited)** 

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2026** | **2025** |
| **Revenues:** |  |  |
| &nbsp;&nbsp;&nbsp;License revenue | $463 | $1163 |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;Research and development | 34528 | 27003 |
| &nbsp;&nbsp;General and administrative | 12468 | 7337 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 46996 | 34340 |
| Loss from operations | (46533) | (33177) |
| Other income/(expense): |  |  |
| &nbsp;&nbsp;Interest and investment income | 6265 | 3791 |
| &nbsp;&nbsp;Loss on investment in former related party | (302) | (5) |
| &nbsp;&nbsp;Loss on currency exchange, net | (15) | (22) |
| &nbsp;&nbsp;Other expense | (249) | (98) |
| &nbsp;&nbsp;Total other income | 5699 | 3666 |
| Net loss | $(40834) | $(29511) |
| Net loss per share attributable to common stockholders,<br> basic and diluted | $(0.85) | $(0.82) |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-average number of shares of common stock outstanding <br>&nbsp;&nbsp;&nbsp;&nbsp;including shares issuable under equity-classified pre-funded <br>&nbsp;&nbsp;&nbsp;&nbsp;warrants, used in computing net loss per share of common stock, <br>&nbsp;&nbsp;&nbsp;&nbsp;basic and diluted | 48032742 | 35790700 |
| Comprehensive loss: |  |  |
| &nbsp;&nbsp;Net loss | $(40834) | $(29511) |
| &nbsp;&nbsp;Other comprehensive (loss)/income: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized (loss)/gain on marketable securities | (1064) | 164 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive (loss)/income | (1064) | 164 |
| Total comprehensive loss | $(41898) | $(29347) |

---

www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036

------